JPWO2020154540A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020154540A5 JPWO2020154540A5 JP2021543170A JP2021543170A JPWO2020154540A5 JP WO2020154540 A5 JPWO2020154540 A5 JP WO2020154540A5 JP 2021543170 A JP2021543170 A JP 2021543170A JP 2021543170 A JP2021543170 A JP 2021543170A JP WO2020154540 A5 JPWO2020154540 A5 JP WO2020154540A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- composition
- domain
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000039446 nucleic acids Human genes 0.000 claims description 20
- 108020004707 nucleic acids Proteins 0.000 claims description 20
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 239000013604 expression vector Substances 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024229904A JP2025060876A (ja) | 2019-01-23 | 2024-12-26 | 抗ｃｄ３８結合ドメイン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962795855P | 2019-01-23 | 2019-01-23 | |
| US62/795,855 | 2019-01-23 | ||
| PCT/US2020/014845 WO2020154540A1 (en) | 2019-01-23 | 2020-01-23 | Anti-cd38 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024229904A Division JP2025060876A (ja) | 2019-01-23 | 2024-12-26 | 抗ｃｄ３８結合ドメイン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022518282A JP2022518282A (ja) | 2022-03-14 |
| JP2022518282A5 JP2022518282A5 (https=) | 2023-02-01 |
| JPWO2020154540A5 true JPWO2020154540A5 (https=) | 2023-02-01 |
Family
ID=69740548
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543170A Withdrawn JP2022518282A (ja) | 2019-01-23 | 2020-01-23 | 抗ｃｄ３８結合ドメイン |
| JP2024229904A Pending JP2025060876A (ja) | 2019-01-23 | 2024-12-26 | 抗ｃｄ３８結合ドメイン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024229904A Pending JP2025060876A (ja) | 2019-01-23 | 2024-12-26 | 抗ｃｄ３８結合ドメイン |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11414496B2 (https=) |
| EP (1) | EP3914358A1 (https=) |
| JP (2) | JP2022518282A (https=) |
| CN (1) | CN113710324B (https=) |
| AR (1) | AR119677A1 (https=) |
| AU (1) | AU2020211407A1 (https=) |
| CA (1) | CA3127624A1 (https=) |
| TW (1) | TWI863959B (https=) |
| WO (1) | WO2020154540A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113454108B (zh) | 2019-01-23 | 2025-02-14 | 米伦纽姆医药公司 | 包含去免疫化志贺菌毒素a亚基效应子的cd38结合蛋白 |
| AR119677A1 (es) | 2019-01-23 | 2022-01-05 | Millennium Pharm Inc | Dominios de unión anti-cd38 |
| CA3180690A1 (en) * | 2020-06-17 | 2021-12-23 | Ahmed Mahiuddin | Cd38 antibodies for treatment of human diseases |
| WO2023172983A1 (en) * | 2022-03-08 | 2023-09-14 | Molecular Templates, Inc. | Ctla-4 binding molecules comprising shiga toxin a subunit scaffolds and uses thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| CZ295838B6 (cs) | 1996-09-09 | 2005-11-16 | Zealand Pharma A/S | Způsob výroby peptidů |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| EP0915987A2 (en) | 1997-04-21 | 1999-05-19 | Donlar Corporation | POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7449443B2 (en) | 2000-03-23 | 2008-11-11 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
| US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| US7139665B2 (en) | 2002-02-27 | 2006-11-21 | California Institute Of Technology | Computational method for designing enzymes for incorporation of non natural amino acids into proteins |
| EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
| EP1675620B1 (en) | 2003-10-09 | 2019-05-08 | Ambrx, Inc. | Polymer derivatives |
| EP2327724A3 (en) | 2004-02-02 | 2011-07-27 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US7887801B2 (en) | 2007-07-13 | 2011-02-15 | Topotarget Germany Ag | Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| RS60280B1 (sr) | 2013-03-12 | 2020-06-30 | Molecular Templates Inc | Citotoksični proteini koji sadrže ciljane vezujuće regione za ćelije i regioni shiga toksina a podjedinice za selektivno ubijanje određenih vrsta ćelija |
| ES2774976T3 (es) | 2013-04-29 | 2020-07-23 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado |
| US20160177284A1 (en) | 2014-01-27 | 2016-06-23 | Molecular Templates, Inc. | Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions |
| CN111909278B (zh) | 2014-01-27 | 2024-04-09 | 分子模板公司 | Mhc i类表位递送多肽 |
| WO2017019623A2 (en) | 2015-07-26 | 2017-02-02 | Molecular Templates, Inc. | Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes |
| US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| ES2723774T3 (es) | 2014-03-11 | 2019-09-02 | Molecular Templates Inc | Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal |
| AU2015229583B2 (en) | 2014-03-11 | 2020-07-09 | Molecular Templates, Inc. | Proteins comprising amino-terminal proximal Shiga toxin A Subunit effector regions and cell-targeting immunoglobulin-type binding regions |
| US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
| ES2919749T3 (es) | 2014-06-11 | 2022-07-28 | Molecular Templates Inc | Moléculas dirigidas a células citotóxicas resistentes a la escisión por proteasa |
| CA2961439A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
| MX2017010072A (es) | 2015-02-05 | 2017-11-09 | Molecular Templates Inc | Moleculas multivalentes que se enlazan a cd20, las cuales comprenden regiones efectoras de la subunidad a de la toxina shiga, y composiciones enriquecidas de las mismas. |
| AU2016271124C1 (en) * | 2015-05-30 | 2020-05-14 | Molecular Templates, Inc. | De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
| SG11201903693QA (en) * | 2016-11-01 | 2019-05-30 | Genmab Bv | Polypeptide variants and uses thereof |
| WO2018106895A1 (en) | 2016-12-07 | 2018-06-14 | Molecular Templates, Inc. | Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation |
| EP3573648B1 (en) | 2017-01-25 | 2023-11-22 | Molecular Templates, Inc. | Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes |
| US20200190138A1 (en) | 2017-02-28 | 2020-06-18 | Chugai Seiyaku Kabushiki Kaisha | Protein purification with protein l |
| CN113454108B (zh) * | 2019-01-23 | 2025-02-14 | 米伦纽姆医药公司 | 包含去免疫化志贺菌毒素a亚基效应子的cd38结合蛋白 |
| AR119677A1 (es) | 2019-01-23 | 2022-01-05 | Millennium Pharm Inc | Dominios de unión anti-cd38 |
| CN115769181B (zh) | 2021-04-23 | 2025-10-10 | 京东方科技集团股份有限公司 | 一种解锁控制方法、装置、电子设备和计算机可读存储介质 |
-
2020
- 2020-01-23 AR ARP200100174A patent/AR119677A1/es unknown
- 2020-01-23 CN CN202080010821.7A patent/CN113710324B/zh active Active
- 2020-01-23 JP JP2021543170A patent/JP2022518282A/ja not_active Withdrawn
- 2020-01-23 CA CA3127624A patent/CA3127624A1/en active Pending
- 2020-01-23 AU AU2020211407A patent/AU2020211407A1/en active Pending
- 2020-01-23 WO PCT/US2020/014845 patent/WO2020154540A1/en not_active Ceased
- 2020-01-23 US US16/751,107 patent/US11414496B2/en active Active
- 2020-01-23 EP EP20708747.9A patent/EP3914358A1/en active Pending
- 2020-01-30 TW TW109102900A patent/TWI863959B/zh active
-
2022
- 2022-07-01 US US17/810,377 patent/US12312411B2/en active Active
-
2024
- 2024-12-26 JP JP2024229904A patent/JP2025060876A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7138046B2 (ja) | 二特異性抗体基幹 | |
| CN110382529B (zh) | 工程化的异源二聚体蛋白质 | |
| CA2892623C (en) | Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof | |
| JP2017095503A (ja) | 単一ドメイン抗原結合分子の精製方法 | |
| JP2017534296A5 (https=) | ||
| CN107793477A (zh) | 蛋白质纯化 | |
| JP7812230B2 (ja) | ポリペプチド鎖交換による抗体由来ポリペプチドの生成 | |
| WO2017134440A2 (en) | Heterodimers and purification thereof | |
| CA3079793A1 (en) | Bispecific antigen binding construct | |
| US20220033526A1 (en) | Activatable therapeutic multispecific polypeptides with extended half-life | |
| JP7688584B2 (ja) | ポリペプチド鎖の交換により活性化される治療用多重特異性ポリペプチド | |
| JP7826320B2 (ja) | 二重または多重特異性抗体｛Ｂｉ ｏｒ Ｍｕｌｔｉ－Ｓｐｅｃｉｆｉｃ Ａｎｔｉｂｏｄｙ｝ | |
| JPWO2020154540A5 (https=) | ||
| US20230136595A1 (en) | Method for the production and purification of multivalent immunoglobulin single variable domains | |
| KR20230118612A (ko) | 헤테로다이머화를 위한 직교 돌연변이 | |
| JP2025537782A (ja) | 活性化可能なエフェクタードメインを有する組換え結合タンパク質 | |
| CN121712805A (zh) | Ch3结构域变体或包含该ch3结构域变体的双特异性抗体 | |
| JP2025514763A5 (https=) | ||
| US20260098094A1 (en) | Cµ4 REGION FOR PAIRING HEAVY AND LIGHT CHAINS IN MULTI-SPECIFIC ANTIBODIES | |
| WO2026067827A1 (zh) | 一种制备异源多聚体的方法及应用 | |
| JP2026514025A (ja) | 抗ｃｄ２８×抗ｅｎｐｐ３抗体 | |
| HK40062072B (zh) | 通过多肽链交换产生抗体衍生的多肽 | |
| LT6389B (lt) | Dimerinis antikūno fragmentas, neutralizuojantis vaginolizino citolitinį aktyvumą |